https://www.selleckchem.com/pr....oducts/acalabrutinib
90, 95% confidence interval (CI) 0.72-1.13]. The DRA did not decrease RAS (RR 0.43, 95%CI 0.08-2.49) and RAO (RR 0.48, 95%CI 0.18-1.29). Patients with the DRA had a shorter hemostasis time in comparison to those with the RA (mean difference -6.64, 95%CI -10.37 to -2.9. The evidence of certainty was low. For CAG, the DRA would be safer than the RA with comparable cannulation rates. Given the limited data, additional research, including studies with standard protocols, is necessary. For CAG, the DRA would be safer than the RA with